Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias-Reference-Cited by-同舟云学术

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

Published:2018-11-19 Issue:1 Volume:16 Page:
ISSN:1477-7525
Container-title:Health and Quality of Life Outcomes
language:en
Short-container-title:Health Qual Life Outcomes

Author:

Taher Ali T.,Origa Raffaella,Perrotta Silverio,Kouraklis Alexandra,Ruffo Giovan Battista,Kattamis Antonis,Goh Ai-Sim,Huang Vicky,Zia Aiesha,Herranz Raquel Merino,Porter John B.

Funder

This study was funded by Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12955-018-1041-5.pdf

Reference28 articles.

1. Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25:725–42.

2. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi J-F, Phatak PD, Coates TD. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47:1919–29.

3. Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, Romero-Jimenez RM, Sanjurjo-Saez M. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome. J Clin Pharm Ther. 2016;41:59–63.

4. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.

5. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina B, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–62.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets: Is There an Effect on Ferritin Levels in Children and Adolescents with Transfusion-Dependent Anemia?;Turkish Archives of Pediatrics;2024-03-01

2. Challenges of Iron Chelation in Thalassemic Children;Thalassemia Reports;2024-02-01

3. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet;International Journal of Pediatric Otorhinolaryngology;2024-02

4. Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia;Annals of Hematology;2023-05-25

5. Clinical Challenges with Iron Chelation in Beta Thalassemia;Hematology/Oncology Clinics of North America;2023-04